Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen: Novel viral biomarkers for chronic hepatitis B management

Table 2 Summary of the characteristics of quantitative hepatitis B surface antigen assays from several companies

Test names	Companies	Principle techniques	Detection methods	Pretreatment procedure	Range of detection	On-board dilution
Elecsys HBsAg II	Roche Diagnostic	Sandwich technique, 2 capture mAbs, and a mixture of mAbs and polyAbs detection	ECLIA (ruthenium)	None	0.05–130 IU/mL	1:400 with buffered negative human serum
Architect HBsAg QT	Abbott Laboratories	Sandwich technique, capture mAbs, and polyAbs detection	CMIA (acridinium)	None	0.05–250 IU/mL	1:500 with recalcified negative human plasma
Sysmex HISCL HBsAg	Sysmex Corporation	Sandwich technique, capture mAbs, and mAbs detection	CLEIA (CDP-Star)	None	0.03–2500 IU/mL	Auto dilution
Lumipulse G HBsAg-Quant	Fujirebio Incorporation	Sandwich technique, 2 capture mAbs and 2 detections mAbs	CLEIA (AMPPD)	Yes, to disrupt viral particles and dissociate HBsAg from HBsAg-anti-HBs complexes	0.005–150 IU/mL	1:100, 1:200 or 1:1000 with NaCl and Tris buffer
iTACT-HBsAg	Fujirebio Incorporation	Sandwich technique	ICT-CLEIA (AMPPD)	Yes, to inactivate anti-HBs, releases the antigen from the immune complexes, and to disassociate the antigen polymers into monomers	0.0005–113 IU/mL	N/A

AMPPD: Adamantane; CMIA: Chemiluminescent microparticle immunoassay; CLEIA: Chemiluminescent enzyme immunoassay; ECLIA: Electrochemiluminescence immunoassay; ICT-CLEIA: Immune complex transfer-chemiluminescent enzyme immunoassay; iTACT: Immunoassay for total antigen including complex via pretreatment; mAbs: Monoclonal antibodies; polyAbs: Polyclonal antibodies; N/A: Not associated.